ALCLS Cellectis SA

Monthly information on share capital and company voting rights

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority)

PARIS, Dec. 03, 2025 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

DateTotal number of shares

in the capital		Total number of voting rights
11/30/2025100,325,454105,406,812

For further information on Cellectis, please contact:     

Media contacts:

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33,

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contact:

Arthur Stril, Chief Financial Officer & Chief Business Officer,

Attachment



EN
03/12/2025

Underlying

ALCLSCellectis SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cellectis SA

 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Cellectis Announces Arbitral Decision in Dispute with Servier

Cellectis Announces Arbitral Decision in Dispute with Servier NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announces that the Arbitral Tribunal has issued its decision in the arbitration proceedings against Les Laboratoires Servier and Institut de Recherches Internationales Servier IRIS SARL (“Servier”), relating to the License, Development and Commercialization Agreement entered into between Ser...

December 15, 2025 1 EN
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Cellectis annonce la décision du tribunal arbitral dans le litige l’op...

Cellectis annonce la décision du tribunal arbitral dans le litige l’opposant à Servier NEW YORK, 15 déc. 2025 (GLOBE NEWSWIRE) -- Cellectis (la « Société ») (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa plateforme pionnière d'édition de génome pour développer des thérapies cellulaires et géniques innovantes pour le traitement de maladies graves, annonce que le tribunal arbitral a rendu sa décision dans l’arbitrage l’opposant aux sociétés Les Laboratoires Servier et Institut de Recherches Internationales Servier IRIS SARL (“Servier”), ...

December 15, 2025 1 EN
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

ASH 2025 : Cellectis présente son plan de développement pour renforcer...

ASH 2025 : Cellectis présente son plan de développement pour renforcer les taux de réponse élevés obtenus avec éti-cel dans le LNH en rechute ou réfractaire Éti-cel a montré un taux de réponse globale (ORR) de 88 % et un taux de réponse complète (CR) de 63 % (n=8) au niveau de dose actuel chez des patients atteints de LNH en rechute ou réfractaire après au moins deux lignes de traitementDes données in vivo suggèrent que l’ajout à faible dose d’IL-2 pourrait amplifier les taux de réponse et optimiser l’expansion et la persistance d’éti-celLe recrutement de la cohorte IL-2 débutera au 1ᵉʳ tri...

December 8, 2025 1 EN
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

ASH 2025: Cellectis Presents Development Plan to Further Enhance High ...

ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL Eti-cel showed an 88% ORR and 63% CR (n=8) at current dose level in r/r NHL after ≥2 prior lines of therapyIn vivo data suggest IL-2 may further enhance response rates and optimize eti-cel expansion and persistenceIL-2 cohort enrollment to start in Q1 2026; full Phase 1 dataset expected in 2026 NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editin...

December 8, 2025 1 EN
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Monthly information on share capital and company voting rights

Monthly information on share capital and company voting rights (Article 223-16 of General Regulation of the French financial markets authority) PARIS, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights11/30/2025100,325,454105,406,812 For further information on Cellectis, please contact:      Media contacts:Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93 Investor Relations contact:Arthur ...

December 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch